KR900002797A - MAC-1 백혈구 점착 수용체의 α-아단위 - Google Patents

MAC-1 백혈구 점착 수용체의 α-아단위 Download PDF

Info

Publication number
KR900002797A
KR900002797A KR1019890011971A KR890011971A KR900002797A KR 900002797 A KR900002797 A KR 900002797A KR 1019890011971 A KR1019890011971 A KR 1019890011971A KR 890011971 A KR890011971 A KR 890011971A KR 900002797 A KR900002797 A KR 900002797A
Authority
KR
South Korea
Prior art keywords
mac
subunit
condition
functional derivative
mentioned
Prior art date
Application number
KR1019890011971A
Other languages
English (en)
Other versions
KR0185964B1 (ko
Inventor
알랜 스프링거 티모씨
코비 앤젤
Original Assignee
다나 파버 캔서 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다나 파버 캔서 인스티튜트 filed Critical 다나 파버 캔서 인스티튜트
Publication of KR900002797A publication Critical patent/KR900002797A/ko
Application granted granted Critical
Publication of KR0185964B1 publication Critical patent/KR0185964B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

Mac-1 백혈구 점착 수용체의 α-아단위
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제 1 도는 Mac-1의 α아단위 cDNA 클론의 제한지도 및 서열분석 기획도이다.
제 2 도는 Mac-1의 α-아단위의 뉴클레오타이드 서열 및 cDNA-유도된 아미노산 서열을 나타낸다.
제 3 도는 Mac-1 α의 상동성 반복부를 나타낸다.

Claims (42)

  1. 천연 오염물이 실질직으로 없는 Mac-1 α-아단위 또는 이의 작용성 유도체.
  2. 제 1 항에 있어서, 언급된 Mac-1 α-아단위가 세포의 표면상에 존재하는 분자에 추가로 결합할 수 있는 Mac-1 α-아단위 또는 이의 작용성 유도체.
  3. 제 2 항에 있어서, 세포의 표면상에 존재하는 언급된 분가가 iC3b 또는 Mac-1의 다른 천연리간드인 Mac-1 α-아단위.
  4. 제 1 항에 있어서, 언급된 분자가 Mac-1 이종 이량체를 형성하기 위하여 Mac-1 β-아단위와 결합할 수 있는 Mac-1 α-아단위.
  5. 제 4 항에 있어서, 언급된 이종이량체가 iC3b 또는 Mac-1의 다른 천연리가드에 결합할 수 있는 Mac-1 α-아단위.
  6. 제 2 항에 있어서, 언급된 분자가 하기 a내지 n으로 이루어진 그룹중에서 선택되는 적어도 하나의 폴리펩타이드를 추가로 함유하는 Mac-1 α-아단위.
    a. A-N-Q-R-G-S-L ; h. Y-I-L-T-S-H-N ;
    b. M-E-Q-L-K-K-S ; i. C-Q-D-D-L-S-I ;
    c. T-D-G-E-K-F-G ; j. T-I-Q-N-Q-L-G ;
    d. G-V-F-L-Y-T-S ; l. Y-Q-H-I-G-L-V ;
    e. V-D-V-D-S-S-N-G-S-T ; m. L-F-T-A-L-F-P ;
    f. D-V-N-G-D-K-L-T-D-V-A ; n. F-S-L-V-G-T-P.
    g. D-L-T-M-D-G-L-V-D-L ;
  7. 제 2 항에 있어서, 언급된 작용성 유도체가 Mac-1 α-아단위의 단편인 Mac-1 α-아단위의 작용성 유도체.
  8. 제 2 항에 있어서, 언급된 작용성 유도체가 Mac-1 α-아단위의 변이체인 Mac-1 α-아단위의 작용성 유도체.
  9. 제 2 항에 있어서, 언급된 작용성 유도체가 Mac-1 α-아단위의 유사체인 Mac-1 α-아단위의 작용성 유도체.
  10. 제 2 항에 있어서, 언급된 작용성 유도체가 Mac-1 α-아단위의 화학적 유도체인 Mac-1 α-아단위의 작용성 유도체.
  11. Mac-1 α-아단위 또는 이의 작용성 유도체를 발현할 수 있는 재조합 DNA 분자.
  12. 제11항에 있어서, 언급된 Mac-1 α-아단위 또는 이의 작용성 유도체가 하기 a내지 n으로 이루어진 그룹중에서 선택되는 적어도 하나의 폴리펩타이드를 함유하는 DNA분자.
    a. A-N-Q-R-G-S-L ; h. Y-I-L-T-S-H-N ;
    b. M-E-Q-L-K-K-S ; i. C-Q-D-D-L-S-I ;
    c. T-D-G-E-K-F-G ; j. T-I-Q-N-Q-L-R ;
    d. G-V-F-L-Y-T-S ; k. V-Q-S-L-V-L-G ;
    e. V-D-V-D-S-S-N-G-S-T ; l. Y-Q-H-I-G-L-V ;
    f. D-V-N-G-D-K-L-T-D-V-A ; m. L-F-T-A-L-F-P ;
    g. D-L-T-M-D-G-L-V-D-L ; n. F-S-L-V-G-T-P.
  13. 제11항에 따른 재조합 분자의 발현에 의해 생성된 Mac-1 α 분자 또는 이의 작용성 유도체.
  14. Mac-1 α-아단위 및 이의 작용성 유도체로 이루어진 그룹중에서 선택되는 소염제를 염증을 억제하기에 충분한 양으로 이의 치료가 필요한 포유동물에 제공함을 특징으로 하여, 포유동물에서 비-특이적 방어계의 반응으로부터 발생하는 염증을 치료하는 방법.
  15. 제14항에 있어서, 언급된 소염제가 Mac-1 α-아단위인 방법.
  16. 제14항에 있어서, 언급된 소염제가 Mac-1 α-아단위의 작용성 유도체인 방법.
  17. 제14항에 있어서, Mac-1 β-아단위 또는 이의 작용성 유도체를 추가로 투여함을 특징으로 하는 방법.
  18. 제17항에 있어서, 언급된 Mac-1 α-아단위가 재조합 핵산 분자의 발현에 의해 생성되고, 언급된 β-아단위와 결합하여 Mac-1 이종이량체를 형성하는 방법.
  19. 제14항에 있어서, 언급된 소염제를 염증의 개시전에 포유동물에 제공하는 방법.
  20. 제14항에 있어서, 소염제를 장내 방법 및 비경구 방법으로 이루어진 그룹중에서 선택되는 방법으로 투여하는 방법.
  21. 제20항에 있어서, 비경구 방법이 근육내, 정맥내 피하 방법으로 이루어진 그룹중에서 선택되는 방법.
  22. 제14항에 있어서, 염증이 성인성 호흡곤란 증후군(adult respiratory distress syndrome), 아테롬성 동맥경화증(atherosclerosis), 패혈증에 따른 다발성 기관 손상 증후군(multiple organ injury syndrome secondary to septicemia), 외상에 따른 다발성 기관손상 증후군(multiple organ injury syndrome secondary to trauma), 조직의 재관류 손상(reperfusion injury of tissue), 급성 사구체신염(acute glomerulonephritis), 반응성 관절염(reactive arthritis), 급성 염증 성분에 의한 피부병(dermatosis with acute inflammatory components), 중추 신경계 염증 장애(central nervous system inflammatory disorder), 열상(thermal injury), 혈액투석증(hemodialysis), 류카페레시스(leukapheresis), 궤양성 대장염(ulcerative colitis), 크론 질환(Crohn's disease), 괴사성 소장결장염(necrotizing enterocolitis), 과립구 수혈 관련된 증후군(granulocyte transfusion associated syndrome), 사이토킨-유발된 독성(cytokin-induced toxicity), 및 아테롬성 동맥경화증(atherosclerosis)으로 이루어진 그룹중에서 선택된 증세와 관련되는 방법.
  23. 제22항에 있어서, 증세가 성인성 호흡 곤란 증후군인 방법.
  24. 제22항에 있어서, 증세가 패혈증에 따른 다발성 기관손상 증후군인 방법.
  25. 제22항에 있어서, 증세가 외상에 따른 다발성 기관손상 증후군인 방법.
  26. 제22항에 있어서, 증세가 조직의 재관류 손상인 방법.
  27. 제27항에 있어서, 재관류 손상이 심근조직의 재관류 손상인 방법.
  28. 제22항에 있어서, 증세가 급성 사구체신염인 방법.
  29. 제22항에 있어서, 증세가 반응성 관절염인 방법.
  30. 제22항에 있어서, 증세가 급성 염증 성분에 의한 피부병인 방법.
  31. 제22항에 있어서, 증세가 중추신경계 염증 장애인 방법.
  32. 제22항에 있어서, 중추신경계 염증 장애가 급성화농성 뇌막염인 방법.
  33. 제22항에 있어서, 증세가 열상인 방법.
  34. 제22항에 있어서, 증세가 혈액투석증인 방법.
  35. 제22항에 있어서, 증세가 류카페레시스인 방법.
  36. 제22항에 있어서, 증세가 궤양성 대장염인 방법.
  37. 제22항에 있어서, 증세가 크론 질환인 방법.
  38. 제22항에 있어서, 증세가 괴사성 소장결장염인 방법.
  39. 제22항에 있어서, 과립수 수혈 관련된 증후군인 방법.
  40. 제22항에 있어서, 증세가 사이토킨-유발된 독성인 방법.
  41. 제22항에 있어서, 증세가 아테롬성 동맥경화증인 방법.
  42. Mac-1 α-아단위, 또는 이의 작용성 유도체를 함유하는 조성물을 유효량으로 치료가 필요한 포유동물에 제공함을 특징으로 하여, 비루스 감염을 치료하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890011971A 1988-08-23 1989-08-23 MAC-1 백혈구 점착 수용체의 α-아단위 KR0185964B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23535388A 1988-08-23 1988-08-23
US7/235,353 1988-08-23
US32123989A 1989-03-09 1989-03-09
US321,239 1989-03-09

Publications (2)

Publication Number Publication Date
KR900002797A true KR900002797A (ko) 1990-03-23
KR0185964B1 KR0185964B1 (ko) 1999-05-01

Family

ID=26928829

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890011971A KR0185964B1 (ko) 1988-08-23 1989-08-23 MAC-1 백혈구 점착 수용체의 α-아단위

Country Status (13)

Country Link
US (3) US5849896A (ko)
EP (1) EP0364690A3 (ko)
JP (1) JPH0347077A (ko)
KR (1) KR0185964B1 (ko)
AU (1) AU638937B2 (ko)
CA (1) CA1341293C (ko)
DK (1) DK412489A (ko)
FI (1) FI893917A (ko)
HU (1) HU213014B (ko)
IL (1) IL91370A (ko)
NO (1) NO893367L (ko)
NZ (1) NZ230397A (ko)
PT (1) PT91502B (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006592A1 (en) * 1987-02-26 1988-09-07 Dana-Farber Cancer Institute, Inc. Cloning of lfa-1
US5395929A (en) * 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
US5877275A (en) * 1988-06-28 1999-03-02 The General Hospital Corporation Controlling cellular immune/inflammatory responses with β2 integrins
EP0364690A3 (en) 1988-08-23 1990-07-18 Dana Farber Cancer Institute The alpha-subunit of the mac-1 leukocyte adhesion receptor
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
JPH04505613A (ja) * 1989-03-09 1992-10-01 ダナ・ファーバー・キャンサー・インスティチュート 白血球付着レセプター
EP0462184A4 (en) * 1989-03-09 1992-01-08 Dana Farber Cancer Institute Method of treating viral infections using lfa-1
EP0468257B1 (en) * 1990-07-20 1999-09-01 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
JPH08502956A (ja) * 1992-10-09 1996-04-02 センター、フォー、ブラッド、リサーチ、インコーポレーテッド ＩＣＡＭ‐１及びフィブリノーゲンへの好中球接着を媒介するＭａｃ‐１（ＣＤ１１ｂ／ＣＤ１８）分子のサブ集団
EP0758393A1 (en) * 1994-04-26 1997-02-19 PHARMACIA & UPJOHN COMPANY Mac-1 i-domain protein useful in blocking adhesion and migration of neutrophils
JPH10506608A (ja) * 1994-07-11 1998-06-30 アセナ ニューロサイエンシーズ，インコーポレイテッド 白血球接着のインヒビター
US5696229A (en) * 1995-03-16 1997-12-09 The University Of Virginia Patent Foundation Polypeptide with laminin cell adhesion and morphogenesis activity
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US7400477B2 (en) 1998-08-24 2008-07-15 Leviton Manufacturing Co., Inc. Method of distribution of a circuit interrupting device with reset lockout and reverse wiring protection
US6210897B1 (en) 1999-05-26 2001-04-03 Leif Andersson Identification of canine leukocyte adhesion deficiency in dogs
AU4574501A (en) 2000-03-17 2001-10-03 Millennium Pharm Inc Method of inhibiting stenosis and restenosis
CA2417432C (en) 2000-09-01 2010-11-02 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
US7372678B2 (en) * 2005-08-24 2008-05-13 Leviton Manufacturing Co., Inc. Circuit interrupting device with automatic test
US7852606B2 (en) * 2005-08-24 2010-12-14 Leviton Manufacturing Company, Inc. Self-testing circuit interrupting device
US7911746B2 (en) * 2006-06-01 2011-03-22 Leviton Manufacturing Co., Inc. GFCI with self-test and remote annunciation capabilities
US8603628B2 (en) * 2007-04-30 2013-12-10 Saint-Gobain Performance Plastics Corporation Turbine blade protective barrier
WO2009097469A1 (en) 2008-01-29 2009-08-06 Leviton Manufacturing Co., Inc. Self testing fault circuit interrupter apparatus and method
US9759758B2 (en) 2014-04-25 2017-09-12 Leviton Manufacturing Co., Inc. Ground fault detector

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761371A (en) * 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
US5424399A (en) * 1988-06-28 1995-06-13 The Children's Medical Center Corporation Human CR3α/β heterodimers
EP0364690A3 (en) 1988-08-23 1990-07-18 Dana Farber Cancer Institute The alpha-subunit of the mac-1 leukocyte adhesion receptor

Also Published As

Publication number Publication date
US20020022595A1 (en) 2002-02-21
PT91502B (pt) 1995-05-04
US5849896A (en) 1998-12-15
NZ230397A (en) 1997-07-27
IL91370A0 (en) 1990-04-29
CA1341293C (en) 2001-09-18
US6683158B2 (en) 2004-01-27
DK412489A (da) 1990-02-24
KR0185964B1 (ko) 1999-05-01
EP0364690A2 (en) 1990-04-25
DK412489D0 (da) 1989-08-22
EP0364690A3 (en) 1990-07-18
JPH0347077A (ja) 1991-02-28
FI893917A (fi) 1990-02-24
HU213014B (en) 1997-01-28
HUT54207A (en) 1991-01-28
NO893367L (no) 1990-02-26
PT91502A (pt) 1990-03-08
AU4014489A (en) 1990-03-01
FI893917A0 (fi) 1989-08-21
AU638937B2 (en) 1993-07-15
IL91370A (en) 1995-07-31
NO893367D0 (no) 1989-08-22
US20030013850A1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
KR900002797A (ko) MAC-1 백혈구 점착 수용체의 α-아단위
Medof et al. Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement.
ALLAN et al. Glycoprotein receptors for concanavalin A isolated from pig lymphocyte plasma membrane by affinity chromatography in sodium deoxycholate
Holers et al. The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function
Nisco et al. Induction of allograft tolerance in rats by an HLA class-I-derived peptide and cyclosporine A.
Ohta et al. Extracellular adenosine-mediated modulation of regulatory T cells
Chauvet et al. The reactive site of the basic trypsin inhibitor of pancreas: role of lysine 15
Sun et al. Advances in understanding the roles of CD244 (SLAMF4) in immune regulation and associated diseases
Moretta et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis
JP3320774B2 (ja) 薬剤組成物
Desbois et al. Natural killer cells in non-hematopoietic malignancies
JPH05329207A (ja) エンドトキシン中和剤
Falk et al. Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells
Lee et al. Importance of treatment regimen of interferon as an antitumor agent
Timmons et al. Antiplatelet" hybrid" peptides analogous to receptor recognition domains on. gamma. and. alpha. chains of human fibrinogen
AU2002358950B2 (en) Migration of hematopoietic stem cells and progenitor cells to the liver
WO1993003049A1 (en) New ganglioside derivatives
Liu et al. Comparison of protein structure and genomic structure of human, rabbit, and Limulus C-reactive proteins: possible implications for function and evolution
Kariniemi et al. Effect of leucocyte interferon on natural killer cells in healthy volunteers
US4816441A (en) Peptides and compositions
McPhaden et al. The complement system in sepsis and trauma
Shitara et al. Natural killer (NK) cell activating factor released from murine thymocytes stimulated with an anti-tumor streptococcal preparation, OK-432.
JP3228548B2 (ja) 肺胞酸素毒性阻害用医薬製剤
Cavill Iron status indicators: hello new, goodbye old?
Barnum et al. Molecular analysis of the murine C4b-binding protein gene. Chromosome assignment and partial gene organization

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20111220

Year of fee payment: 14

FPAY Annual fee payment

Payment date: 20121221

Year of fee payment: 15

EXPY Expiration of term